Data are available from the Norwegian Mother and Child Cohort study for researchers who meet the criteria for access to confidential data; <https://www.fhi.no/en/more/research--access-to-data/>.

Introduction {#sec005}
============

Up to 20% of women are estimated to experience sleep problems and symptoms of anxiety during pregnancy \[[@pone.0181042.ref001], [@pone.0181042.ref002]\]. Between 1 and 3% of Norwegian women use benzodiazepine (BZD) or z-hypnotic drugs to treat anxiety disorders or insomnia while pregnant \[[@pone.0181042.ref003]\]. These medications have sedative, hypnotic, anxiolytic, anticonvulsant, and muscle-relaxing effects depending primarily on how long they act on the gamma-aminobutyric acid (GABA~A~) receptor \[[@pone.0181042.ref004]\]. BZDs and z-hypnotics cross the placenta and have the potential to bind to receptors in the developing embryonal/fetal central nervous system \[[@pone.0181042.ref005]\]. It has been proposed that exposure to medications that mimic GABA at GABA~A~ receptors also trigger apoptotic neurodegeneration in the developing brain \[[@pone.0181042.ref006]\].

In the 1980s, a number of rat studies consistently showed that prenatal exposure to BZDs resulted in behavioral deficits and altered brain function \[[@pone.0181042.ref007]--[@pone.0181042.ref011]\]. Withdrawal syndrome and floppy infant syndrome have been reported in babies after maternal use of BZDs towards the end of pregnancy \[[@pone.0181042.ref012]--[@pone.0181042.ref015]\]. Results of previous studies on mental health outcomes in the offspring following prenatal exposure to BZDs or z-hypnotic drugs have been conflicting \[[@pone.0181042.ref016]--[@pone.0181042.ref018]\]. A sibling-matched study found no association with behavioral deviation in children at age 8--12 months after prenatal exposure to medazepam \[[@pone.0181042.ref016]\]. In contrast, a study on 1.5-year-old children showed reduced personal-social behavior abilities in children exposed to BZDs \[[@pone.0181042.ref017]\]. The only published investigation of behavioral outcomes in children older than 1.5 years following prenatal exposure to BZDs was a retrospective study based on 15 exposed children, which found no effects on behavior at the age of 9--10 years \[[@pone.0181042.ref018]\]. None of these studies controlled for indication for use in the mother.

Well-designed observational studies and randomized controlled trials (RCTs) have been called for to resolve these conflicting findings \[[@pone.0181042.ref019]\], but because RCTs involving pregnant women are ethically problematic, observational studies addressing confounding by indication and other potential confounders take precedent \[[@pone.0181042.ref020]\]. In this study, using data from the Norwegian Mother and Child cohort study (MoBa), we aimed to evaluate whether prenatal exposure to BZDs and z-hypnotics affects internalizing or externalizing behavior problems in children at ages 1.5 and 3 years. Such problems are characterized respectively by negative mood states and behavioral inhibition and by behavioral disinhibition \[[@pone.0181042.ref021]\]. Genetic or familial environmental determinants might result in an increased risk of both mood disorders and anxiety in the mother and behavioral problems in the infant, and living with a mother with these disorders could affect a child's behavior. To reduce confounding by family conditions, we performed sibling-matched analyses using fixed-effect (FE) models as a conservative approach to adjust for shared familial confounding. To control for indications that vary over time and could confound the sibling comparisons, we used propensity scores (PS) to adjust for indication for use (sleep problems, symptoms of anxiety and depression) and other potential confounding factors.

Materials and methods {#sec006}
=====================

Data collection {#sec007}
---------------

Data were extracted from the ongoing MoBa study conducted by the Norwegian Institute of Public Health. MoBa is a prospective population-based cohort study following over 100,000 pregnancies \[[@pone.0181042.ref022]\]. Enrollment in the study started in 1999 and was completed in 2008. The participation rate at first assessment was 40.6%. Mothers reported a range of sociodemographic, medical, and psychological information by filling out questionnaires at gestational weeks (gw) 17 and 30 and at 6, 18, and 36 months postpartum (with response rates of 95%, 92%, 87%, 77%, and 62%, respectively). We used the seventh version of the dataset, which is quality-assured and was released in 2013 \[<http://www.fhi.no/moba-en>\].

The Medical Birth Registry of Norway (MBRN) includes information on pregnancy, delivery, and neonatal health on all births in Norway \[[@pone.0181042.ref023]\]. The MoBa and MBRN data were linked via personal identification numbers.

The research project is approved by the Regional Committees for Medical and Health Research Ethics (REK) (2015/1897), and the MoBa study has a license from the Norwegian Data Inspectorate. Written informed consent was obtained from all participants.

Study population {#sec008}
----------------

This study was based on data for 71,996 children whose mothers had returned the 1.5-year follow-up questionnaire and 55,081 children whose mothers had returned the 3-year follow-up questionnaire. Within this cohort, a total of 19,297 siblings were included at 1.5 years and 13,779 siblings at 3 years. All live-born singletons were included in the study population; twins and triplets (N = 4305) and infants born with major malformations (N = 2970) ([Fig 1](#pone.0181042.g001){ref-type="fig"}) were excluded.

![Flow chart of participants.](pone.0181042.g001){#pone.0181042.g001}

BZD and z-hypnotics exposure {#sec009}
----------------------------

BZDs included drugs classified in Anatomical Therapeutic Chemical (ATC) groups N05BA (diazepam, oxazepam, alprazolam), N05CD (nitrazepam, midazolam, flunitrazepam), N03AE01 (clonazepam). Z-hypnotics included drugs classified in the ATC group N05CF (zopiclone and zolpidem). Drug classification was based on the ATC classification system developed by the WHO Collaborating Centre for Drug Statistics Methodology \[[@pone.0181042.ref024]\]. Women reported information about illnesses they experienced throughout their pregnancy and medication used for these illnesses in two prenatal (17 gw, 30 gw) and one postnatal questionnaire (6 months postpartum) covering three time periods: 0 to 13 gw and 14 to 29 gw, and from 30 gw to birth. The women were defined as users of BZDs and z-hypnotics if they had reported use of any BZD or z-hypnotic drug (ATC groups N05BA, N05CD, N05CF, and N03AE01) during pregnancy on at least one of the three questionnaires. Short-term use was defined as reported use in one pregnancy period only (0--13, 14--29, 30--birth), and long-term use was defined as reported use in two or more pregnancy periods. Separate analyses were also performed for the most commonly reported drug groups: BZD-anxiolytics and z-hypnotics. The drug groups of BZDs and z-hypnotics used, as well as the number of siblings discordantly exposed, are described in [Table 1](#pone.0181042.t001){ref-type="table"}.

10.1371/journal.pone.0181042.t001

###### Number of pregnant women reporting use of BZDs or z-hypnotics[^a^](#t001fn002){ref-type="table-fn"}.

![](pone.0181042.t001){#pone.0181042.t001g}

  Drug group                                             Number of children   Number of discordant siblings   Number of children   Number of discordant siblings
  ------------------------------------------------------ -------------------- ------------------------------- -------------------- -------------------------------
  Any benzodiazepine or z-hypnotics                      577 (0.80)           183                             440 (0.80)           145
  *Duration of use*                                                                                                                
  Short-term use[^b^](#t001fn003){ref-type="table-fn"}   463 (0.64)           157                             351 (0.64)           123
  Long-term use[^c^](#t001fn004){ref-type="table-fn"}    114 (0.16)           26                              89 (0.16)            22
  *Drug subgroups*                                                                                                                 
  BZD-anxiolytics                                        315 (0.44)           108                             236 (0.43)           84
  BZD-hypnotics                                          44 (0.06)            12                              35 (0.06)            8
  BZD-anti-epileptics                                    19 (0.03)            6                               12 (0.02)            8
  Z-hypnotics                                            241 (0.34)           75                              192 (0.35)           59

Abbreviations: BZD, benzodiazepines; z-hypnotics, benzodiazepine-related hypnotics

^a^ Some women may have reported use related to several drug groups.

^b^ Short-term use was defined as reported use in one pregnancy period only.

^c^ Long-term use was defined as reported use in two or more pregnancy periods.

Behavior outcomes {#sec010}
-----------------

The Child Behavior Checklist (CBCL), a validated and widely used measure of child behavior, was used at 1.5 and 3 years \[[@pone.0181042.ref025]\]. In MoBa, a shortened version of the CBCL was used; it covers both externalizing (i.e., aggression, attention problems) and internalizing behavior (i.e., anxiousness, emotional reactivity, somatic complaints) and is representative of the full scale \[[@pone.0181042.ref026]\]. Items were selected by a team of four clinical and developmental psychologists, based on clinical and theoretical standards, as well as empirical representativeness (high factor loadings) for behavior problems. The questionnaire consisted of 13 items at 1.5 years and 21 items at 3 years, covering externalizing behavior and internalizing behavior. Externalizing behavior was measured by eight items at 1.5 years and 12 items at 3 years, and internalizing behavior was measured by five items at 1.5 years and nine items at 3 years. These domains predict later psychopathology in children and adolescents \[[@pone.0181042.ref027]\]. The questions were answered on a 3-point scale, as follows: 1 = not true; 2 = somewhat or sometimes true; and 3 = very true or often true. Mean scores were calculated for externalizing and internalizing behaviors, respectively, and standardized z-scores then were computed for both behavioral outcomes.

Potential confounders {#sec011}
---------------------

Confounders were identified by means of a literature review and through use of directed acyclic graphs \[[@pone.0181042.ref028]\] \[[@pone.0181042.ref029]\] (<http://www.dagitty.net/dags.html>) \[[@pone.0181042.ref030]\]. All potential confounders considered are listed in Tables [2](#pone.0181042.t002){ref-type="table"} and [3](#pone.0181042.t003){ref-type="table"}. Information regarding maternal age and parity was retrieved from the MBRN. Information on maternal years of formal education, marital status, pre-pregnancy BMI, sleep problems, chronic disease, and use of folic acid supplements in early pregnancy was retrieved from the first pregnancy questionnaire. Information on alcohol use, illicit drug consumption during pregnancy, and smoking was retrieved from all three pregnancy questionnaires.

10.1371/journal.pone.0181042.t002

###### Maternal characteristics by use of BZDs and z-hypnotics during pregnancy in the 1.5 year MoBa sample.

![](pone.0181042.t002){#pone.0181042.t002g}

                                                                                         Use of BZDs and z-hypnotics                
  -------------------------------------------------------------------------------------- ----------------------------- ------ ----- ------
  Maternal age in years                                                                                                             
   \<25                                                                                  6,948                         9.7    41    7.1
   25--29                                                                                23,807                        33.3   149   25.8
   30--34                                                                                28,130                        39.4   237   41.1
   ≥35                                                                                   12,534                        17.6   150   26.0
  Maternal formal education in years                                                                                                
   \<12                                                                                  4,229                         6.3    55    10.2
   12                                                                                    17,931                        26.6   126   23.3
   13--16                                                                                28,576                        42.4   226   41.9
   ≥17                                                                                   16,594                        24.7   133   24.6
  Marital status                                                                                                                    
   Married or cohabitant                                                                 68,416                        98.1   518   93.0
   Single                                                                                1,357                         1.9    36    7.0
  Maternal BMI                                                                                                                      
   \<25                                                                                  47,712                        69.2   398   71.5
   25--29                                                                                14,936                        21.7   111   19.9
   30--34                                                                                4,618                         6.7    41    7.4
   ≥35                                                                                   1,643                         2.4    7     1.3
  Parity                                                                                                                            
   0                                                                                     32,999                        46.2   282   48.9
   1                                                                                     24,914                        34.9   171   29.6
   ≥2                                                                                    13,506                        18.9   124   21.5
  Maternal smoking                                                                                                                  
   No                                                                                    66,159                        92.6   486   84.2
   Yes                                                                                   5,260                         7.4    91    15.8
  Maternal alcohol use                                                                                                              
   No                                                                                    32,563                        45.8   176   30.7
   Yes, occasionally                                                                     35,958                        50.6   340   59.2
   Yes, often                                                                            2,509                         3.6    58    10.1
  Maternal symptoms of anxiety/depression 17 gw [^a^](#t002fn002){ref-type="table-fn"}                                              
   No                                                                                    67,105                        94.0   456   79.0
   Yes                                                                                   4,314                         6.0    121   21.0
  Maternal symptoms of anxiety/depression 30 gw [^a^](#t002fn002){ref-type="table-fn"}                                              
   No                                                                                    67,377                        94.3   449   77.8
   Yes                                                                                   4,042                         5.7    128   22.2
  Lifetime history of major depression[^b^](#t002fn003){ref-type="table-fn"}                                                        
   No                                                                                    56,089                        78.5   280   48.5
   Yes                                                                                   15,330                        21.5   297   51.5
  Maternal sleep problems                                                                                                           
   No                                                                                    60,361                        84.5   328   56.8
   Yes                                                                                   11,058                        15.5   249   43.2
  Maternal use of illicit drugs[^c^](#t002fn004){ref-type="table-fn"}                                                               
   No                                                                                    71,205                        99.7   538   96.6
   Yes                                                                                   214                           0.3    19    3.4
  Maternal opioid use in pregnancy                                                                                                  
   No                                                                                    70,013                        98.0   499   86.5
   Yes                                                                                   1,406                         2.0    78    13.5
  Maternal SSRI use in pregnancy                                                                                                    
   No                                                                                    70,780                        99.1   489   84.8
   Yes                                                                                   639                           0.9    88    15.3
  Maternal antipsychotic use in pregnancy                                                                                           
   No                                                                                    70,780                        99.1   489   84.8
   Yes                                                                                   639                           0.9    88    15.3
  Maternal triptan use in pregnancy                                                                                                 
   No                                                                                    70,778                        99.1   559   96.9
   Yes                                                                                   641                           0.9    18    3.1
  Maternal NSAID use in pregnancy                                                                                                   
   No                                                                                    66,542                        93.2   485   84.1
   Yes                                                                                   4,877                         6.8    92    15.9
  Maternal use of paracetamol (acetaminophen)                                                                                       
   No use                                                                                39,294                        59.3   224   41.3
   1 pregnancy period                                                                    24,757                        37.3   235   43.4
   2 or 3 pregnancy periods                                                              2,244                         3.2    83    15.3
  Maternal folic acid supplements in early pregnancy                                                                                
   No                                                                                    22,830                        32.0   183   31.7
   Yes                                                                                   48,589                        68.0   394   68.3
  Maternal chronic disease[^d^](#t002fn005){ref-type="table-fn"}                                                                    
   No                                                                                    64,412                        90.2   474   82.2
   Yes                                                                                   7,007                         9.8    103   17.8

SSRI, selective serotonin reuptake inhibitors; NSAID, nonsteroidal anti-inflammatory drug

^a^ Mean score of \>2 on the Hopkins Symptom Checklist (SCL-5)

^b^ Measured in pregnancy week 17; defined as ever having three co-occurring symptoms of depression for at least 2 weeks and admitting to sad mood

^c^ Illicit drug use included hashish, amphetamine, ecstasy, cocaine, or heroin

^d^ Chronic disease included asthma, diabetes treated with insulin, Crohn's disease, arthritis, lupus, epilepsy, multiple sclerosis, or cancer

10.1371/journal.pone.0181042.t003

###### Maternal characteristics by use of BZDs and z-hypnotics during pregnancy in the 3-year MoBa sample.

![](pone.0181042.t003){#pone.0181042.t003g}

                                                                                         Use of BZDs and z-hypnotics                
  -------------------------------------------------------------------------------------- ----------------------------- ------ ----- ------
  Maternal age in years                                                                                                             
   \<25                                                                                  5,058                         9.2    31    7.0
   25--29                                                                                18,170                        33.3   117   26.6
   30--34                                                                                21,720                        39.8   175   39.8
   ≥35                                                                                   9,693                         17.7   117   26.6
  Maternal formal education in years                                                                                                
   \<12                                                                                  2,902                         5.6    37    9.0
   12                                                                                    13,112                        25.4   89    21.5
   13--16                                                                                22,467                        43.5   178   43.1
   ≥17                                                                                   13,164                        25.5   109   26.4
  Marital status                                                                                                                    
   Married or cohabitant                                                                 52,455                        98.2   396   93.2
   Single                                                                                976                           1.8    29    6.8
  Maternal BMI                                                                                                                      
   \<25                                                                                  36,649                        69.4   292   68.9
   25--29                                                                                11,439                        21.7   92    21.7
   30--34                                                                                3,498                         6.6    33    7.8
   ≥35                                                                                   1,249                         2.4    7     1.7
  Parity                                                                                                                            
   0                                                                                     25,851                        47.3   229   52.0
   1                                                                                     18,889                        34.6   120   27.3
   ≥2                                                                                    9,901                         18.1   91    20.7
  Maternal smoking                                                                                                                  
   No                                                                                    50,852                        93.1   376   85.5
   Yes                                                                                   3,789                         6.9    64    14.5
  Maternal alcohol use                                                                                                              
   No                                                                                    25,671                        47.3   147   33.5
   Yes, occasionally                                                                     26,712                        49.2   251   57.2
   Yes, often                                                                            1,946                         3.6    41    9.3
  Maternal symptoms of anxiety/depression 17 gw [^a^](#t003fn002){ref-type="table-fn"}                                              
   No                                                                                    51,510                        94.3   344   78.2
   Yes                                                                                   3,131                         5.7    96    21.8
  Maternal symptoms of anxiety/depression 30 gw [^a^](#t003fn002){ref-type="table-fn"}                                              
   No                                                                                    51,662                        94.6   340   77.3
   Yes                                                                                   2,979                         5.5    100   22.7
  Lifetime history of major depression[^b^](#t003fn003){ref-type="table-fn"}                                                        
   No                                                                                    43,096                        78.9   213   48.4
   Yes                                                                                   11,545                        21.1   227   51.6
  Maternal sleep problems                                                                                                           
   No                                                                                    46,014                        84.2   246   55.9
   Yes                                                                                   8,627                         15.8   194   44.1
  Maternal use of illicit drugs[^c^](#t003fn004){ref-type="table-fn"}                                                               
   No                                                                                    51,071                        99.8   395   96.8
   Yes                                                                                   114                           0.2    13    3.2
  Maternal opioid use in pregnancy                                                                                                  
   No                                                                                    53,558                        98.0   392   89.1
   Yes                                                                                   1,083                         2.0    48    10.9
  Maternal SSRI use in pregnancy                                                                                                    
   No                                                                                    54,163                        99.1   363   82.5
   Yes                                                                                   478                           0.9    77    17.5
  Maternal antipsychotic use in pregnancy                                                                                           
   No                                                                                    54,546                        99.8   416   94.6
   Yes                                                                                   95                            0.2    24    5.4
  Maternal triptan use in pregnancy                                                                                                 
   No                                                                                    54,120                        99.0   426   96.8
   Yes                                                                                   521                           1.0    14    3.2
  Maternal NSAID use in pregnancy                                                                                                   
   No                                                                                    50,871                        93.1   367   83.4
   Yes                                                                                   3,770                         6.9    73    16.6
  Maternal use of paracetamol (acetaminophen)                                                                                       
   No use                                                                                27,971                        54.0   151   35.2
   1 pregnancy period                                                                    13,933                        26.9   124   28.9
   2 or 3 pregnancy periods                                                              9,884                         19,1   154   25.9
  Maternal folic acid supplements in early pregnancy                                                                                
   No                                                                                    16,250                        29.7   124   28.2
   Yes                                                                                   38.391                        70.3   316   71.8
  Maternal chronic disease[^d^](#t003fn005){ref-type="table-fn"}                                                                    
   No                                                                                    49,282                        90.2   361   82.1
   Yes                                                                                   5,359                         9.8    79    17.9

SSRI, selective serotonin reuptake inhibitors; NSAID, nonsteroidal anti-inflammatory drug

^a^ Mean score of \>2 on the Hopkins Symptom Checklist (SCL-5)

^b^ Measured in pregnancy week 17; defined as ever having three co-occurring symptoms of depression for at least 2 weeks and admitting to sad mood

^c^ Illicit drug use included hashish, amphetamine, ecstasy, cocaine, or heroin

^d^ Chronic disease included asthma, diabetes treated with insulin, Crohn's disease, arthritis, lupus, epilepsy, multiple sclerosis, or cancer

Maternal symptoms of depression and anxiety during the pregnancy were reported via a validated short version of the Hopkins Symptom Checklist, the SCL-5, at 17 and 30 gw \[[@pone.0181042.ref031]\]. The 5-item version (SCL-5) has a 0.92 correlation with the original 25-item version. Items in the SCL are scored on a Likert scale ranging from 1 (not at all bothered) to 4 (very much bothered), and scores were calculated as the mean value of the five items. The presence of symptoms of anxiety and depression during pregnancy was defined as 85^th^ percentile or above. Mothers also reported their lifetime history of major depression by answering the lifetime occurrence of five key depressive symptoms chosen from the nine symptomatic criteria for Major Depression in the Diagnostic and Statistical Manual of Mental Disorders III, Revised: sad mood, change in appetite, loss of energy, feelings of guilt or worthlessness, and problems in concentration. They were then asked whether any three of these symptoms co-occurred in their life for at least 2 weeks. As previously recommended, individuals who responded positively to this item and admitted to sad mood were considered to have reported a lifetime history of major depression \[[@pone.0181042.ref032]\].

Maternal concomitant use of other drugs (opioids, selective serotonin reuptake inhibitors (SSRIs), antipsychotics, triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and paracetamol) were reported at 17 and 30 gw and 6 months after birth. Because we previously found an association between long term paracetamol exposure and behavior problems in the child we differentiated between short and long term paracetamol use\[[@pone.0181042.ref033]\].

Statistical methods {#sec012}
-------------------

First, we used random-effects linear regression models to examine crude effect estimates on behavior outcomes at 1.5 and 3 years following prenatal exposure to any BZD or z-hypnotics, short term or long term, for the full MoBa cohort. Random-effects models account for family clusters in the sample by producing standard errors that adjust for dependence between siblings. Separate analyses were performed for BZD-anxiolytics and z-hypnotics.

Second, we performed PS-adjusted random-effect linear regression analyses by including PS as covariates in the analyses. PS were determined with logistic regression models within the complete cohort at 1.5 years and 3 years separately, in which use of any BZD or z-hypnotics was the outcome variable and the predictors were the variables previously selected (see Tables [2](#pone.0181042.t002){ref-type="table"} and [3](#pone.0181042.t003){ref-type="table"}) as confounders during multivariable model building \[[@pone.0181042.ref034]\].

Third, we restricted the sample to multiparous mothers and then carried out sibling-matched FE linear regression using the xtreg function in STATA 14 for FE linear models. As default in STATA, we used the observed information matrix to calculate 95% confidence intervals. In the FE model, each sibling's score on the outcome variables (externalizing and internalizing behaviors) was subtracted from the average scores of all siblings in his/her family, and each sibling's value of the predictor (prenatal exposure to BZDs or z-hypnotics) was subtracted from the average values of all siblings in his/her family. The new outcome variables were regressed on the new exposure variables. The sibling FE models thereby controlled for potential bias by unobserved variables that were fixed within families (constant across siblings), such as shared family environments or genetic transmission of risk (e.g., maternal personality and intellectual ability). The effect estimates are within families of siblings, and only siblings discordant on exposure and outcome contributed any information. Finally, we carried out PS-adjusted FE models to adjust for the potential confounding factors varying between siblings. All analyses were done using Stata Version 14 (Stata Corporation, College Station, TX, USA).

Results {#sec013}
=======

In total, 0.8% of the children were exposed to BZDs and z-hypnotics during pregnancy (N~1.5\ years~ = 577 of 71,996; N~3\ years~ = 440 of 55,081) ([Fig 1](#pone.0181042.g001){ref-type="fig"}).

Internalizing behavior problems {#sec014}
-------------------------------

[Table 4](#pone.0181042.t004){ref-type="table"} shows the results of full cohort (random-effect) and sibling-matched (FE) linear regression models on internalizing behavior problems predicted by *in utero* exposure to BZDs and z-hypnotics, short term, long term, and for BZD-anxiolytics and z-hypnotics separately. Short-term exposure to BZDs and z-hypnotics was associated with increased internalizing behavior problems in crude analyses at both 1.5 and 3 years of child age. These effects were attenuated when accounting for the factors associated with maternal use of BZDs and z-hypnotics during pregnancy by PS score adjustment. For long-term exposure, increasing associations were observed in the sibling-matched models at 1.5 years and were not attenuated after PS score adjustment. At 3 years, crude effects were observed but decreased and were not significant in the PS-adjusted model. However, in the analyses on exposure to BZD-anxiolytics specifically, effect estimates from the sibling-matched model on internalizing behavior remained elevated after adjustment at both 1.5 and 3 years. For z-hypnotics, crude increased internalizing behavior problems were attenuated after adjusting for PS scores and familial confounding in the sibling-matched models.

10.1371/journal.pone.0181042.t004

###### Full cohort and sibling-matched linear regression models: Parameters for differences in internalizing behavior score predicted by *in utero* exposure to BZDs and z-hypnotics.
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                                                                                            Internalizing behavior            
  -------------------------------------------------------------------------------- -------- ------------------------ -------- --------------------
  *Any BZDs and z-hypnotics*                                                                                                  
  Short term[^a^](#t004fn002){ref-type="table-fn"}                                                                            
  Crude cohort sample (re)                                                         71,649   0.12 (0.06, 0.19)        54,741   0.18 (0.10, 0.25)
  PS-adjusted cohort sample (re)[^b^](#t004fn003){ref-type="table-fn"}             60,964   0.07 (0.001, 0.14)       47,767   0.08 (-0.02, 0.16)
  PS-adjusted sibling sample (re) [^b^](#t004fn003){ref-type="table-fn"}           18,193   0.12 (-0.01, 0.25)       13,199   0.15 (-0.01, 0.29)
  Sibling-matched sample (fe)                                                      19,397   0.10 (-0.08, 0.29)       13,711   0.12 (-0.07, 0.32)
  PS-adjusted sibling-matched sample (fe) [^c^](#t004fn004){ref-type="table-fn"}   18,193   0.13 (-0.06, 0.32)       13,199   0.12 (-0.08, 0.32)
  Long term[^a^](#t004fn002){ref-type="table-fn"}                                                                             
  Crude cohort sample (re)                                                         71,649   0.11 (-0.03, 0.24)       54,741   0.21 (0.06, 0.36)
  PS-adjusted cohort sample (re) [^b^](#t004fn003){ref-type="table-fn"}            60,964   0.01 (-0.13, 0.15)       47,767   0.04 (-0.12, 0.20)
  PS-adjusted sibling sample (re) [^b^](#t004fn003){ref-type="table-fn"}           18,193   0.21 (-0.07, 0.49)       13,199   0.06 (-0.25, 0.36)
  Sibling-matched sample (fe)                                                      19,397   0.46 (0.08, 0.85)        13,711   0.21 (-0.19, 0.62)
  PS-adjusted sibling-matched sample (fe) [^c^](#t004fn004){ref-type="table-fn"}   18,193   0.60 (0.17, 0.95)        13,199   0.15 (-0.26, 0.56)
  *Stratified analyses on drug groups*[^d^](#t004fn005){ref-type="table-fn"}                                                  
  BZD-anxiolytics                                                                                                             
  Crude cohort sample (re)                                                         71,649   0.09 (0.003, 0.17)       54,741   0.24 (0.14, 0.34)
  PS-adjusted cohort sample (re) [^b^](#t004fn003){ref-type="table-fn"}            60,964   0.05 (-0.04, 0.14)       47,767   0.13 (0.03, 0.24)
  PS-adjusted sibling sample (re) [^b^](#t004fn003){ref-type="table-fn"}           18,193   0.24 (0.07, 0.41)        13,199   0.23 (0.03, 0.43)
  Sibling-matched sample (fe)                                                      19,397   0.26 (0.02, 0.49)        13,711   0.36 (0.17, 0.55)
  PS-adjusted sibling-matched sample (fe) [^c^](#t004fn004){ref-type="table-fn"}   18,193   0.25 (0.01, 0.49)        13,199   0.26 (0.002,0.52)
  Z-hypnotics                                                                                                                 
  Crude cohort sample (re)                                                         71,649   0.14 (0.05, 0.24)        54,741   0.15 (0.05, 0.25)
  PS-adjusted cohort sample (re) [^b^](#t004fn003){ref-type="table-fn"}            60,964   0.05 (-0.05, 0.15)       47,767   0.02 (-0.09, 0.13)
  PS-adjusted sibling sample (re) [^b^](#t004fn003){ref-type="table-fn"}           18,193   0.01 (-0.17, 0.19)       13,199   0.03 (-0.17, 0.23)
  Sibling-matched sample (fe)                                                      19,397   -0.05 (-0.32, 0.22)      13,711   0.10 (-0.10, 0.30)
  PS-adjusted sibling-matched sample (fe) [^c^](#t004fn004){ref-type="table-fn"}   18,193   0.02 (-0.26, 0.30)       13,199   0.05 (-0.24, 0.35)

CI, confidence interval; re, random effects; fe, fixed effects; PS: propensity score. Effect sizes (β) for all outcomes should be interpreted as the increase in terms of standard deviations in the outcome variable (Cohen's d) in exposed children (reference group: unexposed).

^a^ Three pregnancy periods were defined: gw 0--13, 14--29, 30--birth. Short-term use was defined as reported use in one pregnancy period only. Long-term use was defined as reported use in two or more pregnancy periods.

^b^ Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, formal education, marital status, pre-pregnancy BMI, parity, smoking, or alcohol use during pregnancy, presence of symptoms of anxiety/depression at gw 17 and/or gw 30, lifetime history of major depression, sleep problems, use of illicit drugs, chronic disease, use of folic acid supplements, and use of other medications during pregnancy (opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).

^c^ Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, parity, alcohol use during pregnancy, presence of symptoms of anxiety/depression gw 17 and/or gw 30, lifetime history of major depression, sleep problems, use of illicit drugs, use of folic acid supplements, and use of other medications during pregnancy (opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).

^d^ Including both short- and long-term exposure.

Externalizing behavior problems {#sec015}
-------------------------------

[Table 5](#pone.0181042.t005){ref-type="table"} shows the results of full cohort (random-effect) and sibling-matched (FE) linear regression models for externalizing behavior outcomes predicted by *in utero* exposure to BZDs and z-hypnotics, short term, long term, and for BZD-anxiolytics and z-hypnotics separately. In crude analyses of short-term exposure to BZDs and z-hypnotics, a small increase in externalizing behavior problems was observed at child age 1.5 years, with increasing effect estimates for long-term exposure. Taking PS scores into account, all effects on externalizing behavior problems were attenuated. No effects were observed for externalizing behavior problems in the sibling-matched models for short-term and long-term exposure, accounting for familial confounding, at child age 1.5 or 3 years. In stratified analyses, crude associations with externalizing behavior were observed at 3 years for BZD-anxiolytics and 1.5 years for z-hypnotics. These associations were attenuated when accounting for PS score and familial confounding in the sibling-matched models. At 3 years of age, a beneficial effect of z-hypnotic exposure on externalizing behavior problems was observed after PS score adjustment.

10.1371/journal.pone.0181042.t005

###### Full cohort and sibling-matched linear regression models for externalizing behavior predicted by *in utero* exposure to BZDs and z-hypnotics.

![](pone.0181042.t005){#pone.0181042.t005g}

                                                                                           Externalizing behavior            
  ------------------------------------------------------------------------------- -------- ------------------------ -------- ----------------------
  *Any BZDs and z-hypnotics*                                                                                                 
  Short term[^a^](#t005fn002){ref-type="table-fn"}                                                                           
  Crude cohort sample (re)                                                        71,872   0.08 (0.003, 0.15)       54,709   0.03 (-0.06, 0.12)
  PS-adjusted cohort sample (re) [^b^](#t005fn003){ref-type="table-fn"}           61,537   0.04 (-0.04, 0.12)       47,741   -0.03 (-0.13, 0.06)
  PS-adjusted sibling sample (re)[^b^](#t005fn003){ref-type="table-fn"}           18,248   0.09 (-0.06, 0.25)       13,191   0.001 (-0.19, 0.19)
  Sibling-matched sample (fe)                                                     19,277   0.02 (-0.19, 0.22)       13,701   -0.16 (-0.40, 0.08)
  PS-adjusted sibling-matched sample (fe)[^c^](#t005fn004){ref-type="table-fn"}   18,248   0.02 (-0.19, 0.23)       13,191   -0.15 (-0.76, 0.25)
  Long term[^a^](#t005fn002){ref-type="table-fn"}                                                                            
  Crude cohort sample (re)                                                        71,872   0.22 (0.07, 0.37)        54,709   0.19 (-0.05, 0.32)
  PS-adjusted cohort sample (re)[^b^](#t005fn003){ref-type="table-fn"}            61,537   0.12 (-0.05, 0.28)       47,741   0.09 (-0.10, 0.28)
  PS-adjusted sibling sample (re)[^b^](#t005fn003){ref-type="table-fn"}           18,248   0.20 (-0.13, 0.53)       13,191   0.13 (-0.25, 0.51)
  Sibling-matched sample (fe)                                                     19,277   0.02 (-0.41, 0.44)       13,701   -0.26 (-0.40, 0.08)
  PS-adjusted sibling-matched sample (fe)[^c^](#t005fn004){ref-type="table-fn"}   18,248   -0.03 (-0.46, 0.40)      13,191   -0.25 (-0.76, 0.25)
  *Stratified analyses on drug groups* [^d^](#t005fn005){ref-type="table-fn"}                                                
  BZD-anxiolytics                                                                                                            
  Crude cohort sample (re)                                                        71,872   0.06 (-0.03, 0.16)       54,709   0.13 (0.01, 0.24)
  PS-adjusted cohort sample (re)[^b^](#t005fn003){ref-type="table-fn"}            61,537   0.06 (-0.05, 0.16)       47,741   0.07 (-0.05, 0.20)
  PS-adjusted sibling sample (re)[^b^](#t005fn003){ref-type="table-fn"}           18,248   0.06 (-0.14, 0.25)       13,191   0.31 (0.06, 0.56)
  Sibling-matched sample (fe)                                                     19,277   -0.02 (-0.28, 0.25)      13,701   0.07 (-0.24, 0.39)
  PS-adjusted sibling-matched sample (fe)[^c^](#t005fn004){ref-type="table-fn"}   18,248   -0.04 (-0.31, 0.23)      13,191   0.16 (-0.17, 0.48)
  Z-hypnotics                                                                                                                
  Crude cohort sample (re)                                                        71,872   0.12 (0.02, 0.23)        54,709   0.01 (-0.11, 0.13)
  PS-adjusted cohort sample (re)[^b^](#t005fn003){ref-type="table-fn"}            61,537   0.04 (-0.07, 0.15)       47,741   -0.08 (-0.22, 0.05)
  PS-adjusted sibling sample (re)[^b^](#t005fn003){ref-type="table-fn"}           18,248   0.08 (-0.13, 0.29)       13,191   -0.22 (-0.47, 0.04)
  Sibling-matched sample (fe)                                                     19,277   -0.05 (-0.35, 0.24)      13,701   -0.45 (-0.80, 0.10)
  PS-adjusted sibling-matched sample (fe)[^c^](#t005fn004){ref-type="table-fn"}   18,248   -0.03 (-0.34, 0.28)      13,191   -0.52 (-0.87, -0.15)

CI, confidence interval; re, random effects; fe, fixed effects; PS: propensity score. Effect sizes (β) for all outcomes should be interpreted as the increase in terms of standard deviations in the outcome variable (Cohen's d) in exposed children (reference group: unexposed).

^a^ Three pregnancy periods were defined: gw 0--13, 14--29, 30--birth. Short-term use was defined as reported use in one pregnancy period only. Long-term use was defined as reported use in two or more pregnancy periods.

^b^ Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, formal education, marital status, pre-pregnancy BMI, parity, smoking, or alcohol use during pregnancy, presence of symptoms of anxiety/depression at gw 17 and/or gw 30, lifetime history of major depression, sleep problems, use of illicit drugs, chronic disease, use of folic acid supplements, and use of other medications during pregnancy (opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).

^c^ Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, parity, alcohol use during pregnancy, presence of symptoms of anxiety/depression gw 17 and/or gw 30, lifetime history of major depression, sleep problems, use of illicit drugs, use of folic acid supplements, and use of other medications during pregnancy (opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).

^d^ Including both short- and long-term exposure.

Discussion {#sec016}
==========

In this large prospective follow-up study including siblings discordantly exposed to BZDs or z-hypnotic drugs, we found that prenatal long-term exposure to BZDs or z-hypnotics was associated with increased internalizing behavior problems among children aged 1.5 years. Of importance, when studied separately, BZD-anxiolytics exposure was associated with increased internalizing problems at both 1.5 and 3 years of follow-up while z-hypnotic exposure was not associated with any adverse outcomes.

These findings are in line with previous studies reporting delayed mental functioning up to the age of 1.5 years after exposure to BZDs \[[@pone.0181042.ref017], [@pone.0181042.ref035], [@pone.0181042.ref036]\]. Viggedal et al. observed reduced "personal-social behavior" abilities at child age 1.5 years but found that externalizing problems such as hyperactivity or attention problems were not significantly different from controls \[[@pone.0181042.ref017]\]. This result is in line with our finding that internalizing, not externalizing, problems were reported. Moreover, our study showed effects up to 3 years of age for BZD-anxiolytics. The only previous study looking at child behavior outcomes beyond the age of 1.5 years found no effects on behavior reported at the ages of 9--10 years \[[@pone.0181042.ref018]\]. However, no evaluation of internalizing behavior was reported, and the sample consisted of 15 exposed children, limiting the statistical power to detect effects of exposure \[[@pone.0181042.ref018]\]. It is therefore unclear whether the lack of behavior problems at school age was due to diminishing symptoms, crude measures failing to capture internalizing problems, or low statistical power to detect effects. More prospective follow-up studies with larger sample sizes and measures of internalizing behavior are required to determine the stability of increased internalizing problems beyond preschool age for specific drug groups.

Of note, small associations between z-hypnotic exposure and internalizing behavior problems in the child were attenuated in adjusted analyses taking the indication for use into account. We found no increase in internalizing or externalizing problems in the sibling-matched FE models at any time point for children exposed to z-hypnotic drugs. In contrast, prenatal exposure to z-hypnotics was associated with less externalizing behavior problems at 3 years of age in the sibling-matched analyses. It is possible that using z-hypnotics to reduce sleep problems in pregnancy is beneficial for the child. To our knowledge, no previous study has examined potential long-term effects for the child of prenatal z-hypnotic exposure on behavioral outcomes, and the potential beneficial association between exposure to z-hypnotics and behavioral effects would need to be confirmed by more studies before any conclusions can be made regarding the long-term safety.

The present study has a number of strengths. It uses data from a population-based sample with the possibility of following prospectively more than 400 children prenatally exposed to BZDs and z-hypnotics and a large control group. The richness of the information available enables the opportunity to adjust for many potential confounding factors, including indication for use, which is often not available in conventional studies. Maternal use of BZDs is related to substance abuse and psychiatric problems in the mother \[[@pone.0181042.ref037]\]. Of importance, the sibling-matched design has a number of advantages in controlling for family factors that are difficult to measure and control for in conventional cohort designs. The intra-class correlation across pregnancies for the outcomes are 0.35 (internalizing) and 0.41 (externalizing) (both P \< 0.001) \[[@pone.0181042.ref038]\], showing that stable factors across pregnancies are potentially strong confounders. Because socioeconomic or genetic factors are likely to confound an association between maternal psychotropic medication use during pregnancy and adverse behavioral outcomes in the child, limiting this type of confounding is an important strength.

The study also has some limitations. First, the sibling-controlled design does not rule out factors that vary between siblings, correlate with exposure within families, or correlate with the outcome \[[@pone.0181042.ref039], [@pone.0181042.ref040]\]. The inclusion of an estimated PS in the sibling analyses accounting for the observed factors shown to be associated with BZD and z-hypnotics use helped control for these factors in the current study. Although reported use of illicit drugs and substance use were controlled for, we cannot rule out confounding by more complex misuse not reported in the questionnaires. Second, the design is sensitive to measurement unreliability. Measurement error in the exposure might lead to an underestimation of the effects \[[@pone.0181042.ref041]\]. Moreover, the sample size was not large enough to perform analyses for specific trimesters or on single drugs instead of drug groups in a sibling-controlled design. For the same reason, stratified analyses on child gender were not possible, and gender-specific effects could therefore not be explored. The agreement between self-report and dispensed drugs registered in the Norwegian Prescription Database (NorPD) for drugs used intermittently, such as BZD-anxiolytics and z-hypnotics, is lower than for drugs used chronically \[[@pone.0181042.ref042]\]. This could be because users of BZDs and hypnotics often already have the medications available from previous dispensing. More women reporting BZDs in MoBa were found with a prescription in the NorPD when a longer pre-pregnancy observation period was included \[[@pone.0181042.ref043]\]. In a study based on a linkage between the MBRN and the NorPD including all women giving birth in Norway, 1.5% were reported to use BZDs. In MoBa, only 0.8% reported use, indicating inclusion of healthier women in that study, which may limit the generalizability of the current findings. However, even though estimates of frequencies can be biased due to selective participation, exposure--outcome associations have not previously differed between MoBa participants and the general population \[[@pone.0181042.ref044]\]. Gustavson et al. demonstrated using Monte Carlo simulation studies that association estimates are generally quite robust against selective participation even when the frequency estimates are biased \[[@pone.0181042.ref045], [@pone.0181042.ref046]\].

In conclusion, our results indicate that prenatal exposures to BZDs influence internalizing problems in children. Exposure to BZD-anxiolytic or z-hypnotic medications was not associated with increased externalizing problems. Exposure to BZD-anxiolytics, however, was associated with increased internalizing problems in the child, lasting up to 3 years of age. These findings could not be explained by shared familial confounding, reported indication for use, or other measured confounding factors, but residual unmeasured confounding cannot be ruled out.
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[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
